Prevalence of Sarcopenic Obesity and its Association with Functionality, Lifestyle, Biomarkers and Morbidities in Older Adults: the FIBRA-RJ Study of Frailty in Older Brazilian Adults

Campos, Glaucia Cristina de; Lourenço, Roberto Alves; Lopes, Cláudia S.

doi:10.6061/clinics/2020/e1814

Cited by 9 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In studies using DEXA, the reported prevalence was higher with values ranging from 2.7% to 84% [ 25 , 28 , 38 , 40 , 44 , 45 , 46 , 47 , 48 ]. In a recent analysis of 270 individuals aged 65 years or older who were enrolled in the Frailty in Brazilian Older People Study, the prevalence of sarcopenic obesity was 29.3% with sarcopenic obesity diagnosed via DEXA and defined as a body fat percentage ≥38% or ≥27% and appendicular skeletal muscle mass index (ASMMI) of <5.45 or <7.26 kg/m2 in men or women, respectively [ 49 ].…”

Section: Epidemiology Prevalence and Risk Factorsmentioning

confidence: 99%

Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits

Ali

Nguyen

2021

Life

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) continues to rise and has become the most common cause of chronic liver disease among all ages and ethnicities. Metabolic disorders, such as obesity and insulin resistance, are closely associated with sarcopenia and NAFLD. Sarcopenic obesity is a clinical disorder characterized by the simultaneous loss of skeletal muscle and gain of adipose tissue. It is associated with worse outcomes in individuals with NAFLD. It is projected that NAFLD and sarcopenia will rise as the prevalence of obesity continues to increase at an unparallel rate. Recently, sarcopenia and sarcopenic obesity have gained considerable interest, but we still lack a well-defined definition and a management approach. Therefore, it is imperative to continue shining the light on this topic and better understand the underlying mechanism as well as treatment options. In this review article, we aimed to address the pathophysiology, impact, and outcomes of sarcopenic obesity on NAFLD.

show abstract

Section: Epidemiology Prevalence and Risk Factorsmentioning

confidence: 99%

Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits

Ali

Nguyen

2021

Life

View full text Add to dashboard Cite

show abstract

“…Our study showed that the prevalence of S and SO both gradually increased with aging. Several studies have also proved that the prevalence of S and SO both increased with aging among community-dwelling older people (Alexandre et al, 2014;De Campos et al, 2020). With increasing age, the prevalence of SO showed a rapidly increasing trend in our study, that compared with subjects aged 65-69 years, subjects aged 70-74 years have a 1.923-fold risk of SO, in aged 75-79 years have a 3.185-fold risk of SO, and in age ≥80 years old have a 7.192-fold risk of SO.…”

Section: Figurementioning

confidence: 99%

Prevalence and risk factors of sarcopenia without obesity and sarcopenic obesity among Chinese community older people in suburban area of Shanghai: A cross-sectional study

Song

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

ObjectivesThe aim of the present study was to explore the prevalence and risk factors of sarcopenia without obesity (S) and sarcopenic obesity (SO) among community-dwelling older people in the Chongming District of Shanghai, China, according to the Asian Working Group for Sarcopenia (AWGS) 2019 Consensus as the diagnostic criteria of sarcopenia.MethodsIn this cross-sectional study, a total of 1,407 subjects aged ≥65 years were included, where the mean age of the subjects was 71.91 ± 5.59 years and their mean body mass index (BMI) was 24.65 ± 3.32 kg/m2. According to the Asian Working Group for Sarcopenia (AWGS) 2019 Consensus, sarcopenia was defined as a low appendicular skeletal muscle mass index (≤7.0 kg/m2 in males and ≤5.7 kg/m2 in females), decreased handgrip strength (<28.0 kg in males and <18.0 kg in females), and/or low gait speed (<1.0 m/s) or poor 5-time chair stand test (5CST) (≥12s). The SO met both the diagnostic criteria for sarcopenia and obesity, meanwhile obesity was defined as an increased percentage of body fat (PBF) (≥25% in males and ≥35% in females). Univariate and multiple logistic regression analyses were performed to explore the risk factors of both S and SO.ResultsThe prevalence of S and SO was 9.74% (M: 9.29%, F: 10.05%) and 9.95% (M: 13.94%, F: 7.14%). Lower BMI (OR = 0.136, 95% CI: 0.054–0.340, p < 0.001), lower hip circumference (OR = 0.858, 95% CI: 0.816–0.903, p < 0.001), farming (OR = 1.632, 95% CI: 1.053–2.530, p = 0.028), higher high-density lipoprotein cholesterol (HDL-C) level (OR = 2.235, 95% CI: 1.484–3.367, p < 0.001), and a sleep duration <7 h (OR = 0.561, 95% CI: 0.346–0.909, p = 0.019) were risk factors for S. While aging (70–74 y, OR = 1.923, 95% CI: 1.122–3.295, p = 0.017; 75–79 y, OR = 3.185, 95% CI: 1.816–5.585, p < 0.001; ≥80 y, OR = 7.192, 95% CI: 4.133–12.513, p < 0.001), male (OR = 1.981, 95% CI: 1.351–2.904, p < 0.001), higher BMI (OR = 4.865, 95% CI: 1.089–21.736, p = 0.038), higher monocyte level (OR = 4.203, 95% CI: 1.340–13.181, p = 0.014), and a sleep duration >9 h (OR = 1.881, 95% CI: 1.117–3.166, p = 0.017) were risk factors for SO.ConclusionOur study showed the high prevalence of S and SO among community-dwelling older people in the Chongming District. The SO was more prevalent in males. Behavioral factors and lifestyle (such as farming and sleep duration) were associated more with the development of S, while age and male gender were associated more with the development of SO.

show abstract

“…Older adults with lower appendicular muscle mass divided by total fat mass walk slower than people with higher total fat mass [ 36 , 37 ]. These results often extend to individuals diagnosed with sarcopenic obesity [ 38 , 39 , 40 ]. Given the relatively pervasive nature of this functional association, most clinical studies on individuals with sarcopenic obesity use a walking speed criterion of ≤0.8 m/s as a distinguishing characteristic [ 40 , 41 ].…”

Section: Biomechanics and Gait Performancementioning

confidence: 99%

“…However, gait biomechanics in those with obesity, per se, is considerably better understood than those in people with sarcopenic obesity. Those with sarcopenic obesity walk slower than age-matched individuals without sarcopenic obesity [ 36 , 37 , 38 , 39 ]. Older adults with lower appendicular muscle mass divided by total fat mass walk slower than people with higher total fat mass [ 36 , 37 ].…”

Section: Biomechanics and Gait Performancementioning

confidence: 99%

Multimodal Diagnostic Approaches to Advance Precision Medicine in Sarcopenia and Frailty

et al. 2022

View full text Add to dashboard Cite

Sarcopenia, defined as the loss of muscle mass, strength, and function with aging, is a geriatric syndrome with important implications for patients and healthcare systems. Sarcopenia increases the risk of clinical decompensation when faced with physiological stressors and increases vulnerability, termed frailty. Sarcopenia develops due to inflammatory, hormonal, and myocellular changes in response to physiological and pathological aging, which promote progressive gains in fat mass and loss of lean mass and muscle strength. Progression of these pathophysiological changes can lead to sarcopenic obesity and physical frailty. These syndromes independently increase the risk of adverse patient outcomes including hospitalizations, long-term care placement, mortality, and decreased quality of life. This risk increases substantially when these syndromes co-exist. While there is evidence suggesting that the progression of sarcopenia, sarcopenic obesity, and frailty can be slowed or reversed, the adoption of broad-based screening or interventions has been slow to implement. Factors contributing to slow implementation include the lack of cost-effective, timely bedside diagnostics and interventions that target fundamental biological processes. This paper describes how clinical, radiographic, and biological data can be used to evaluate older adults with sarcopenia and sarcopenic obesity and to further the understanding of the mechanisms leading to declines in physical function and frailty.

show abstract

Prevalence of Sarcopenic Obesity and its Association with Functionality, Lifestyle, Biomarkers and Morbidities in Older Adults: the FIBRA-RJ Study of Frailty in Older Brazilian Adults

Cited by 9 publications

References 50 publications

Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits

Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease—The Union of Two Culprits

Prevalence and risk factors of sarcopenia without obesity and sarcopenic obesity among Chinese community older people in suburban area of Shanghai: A cross-sectional study

Multimodal Diagnostic Approaches to Advance Precision Medicine in Sarcopenia and Frailty

Contact Info

Product

Resources

About